Want to see PRAX full AI Analyst Report?
PRAX Stock Chart & Stats
$342.50
-$2.82(-3.64%)
At close: 4:00 PM EST
$342.50
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$37.19 - $366.52
Previous CloseN/A
Volume51.58K
Average Volume (3M)620.04K
Market Cap
$9.06B
Enterprise Value$5.17B
Total Cash (Recent Filing)$786.87M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 10, 2026EPS Estimate
-3.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.39
Shares Outstanding27,878,775
10 Day Avg. Volume470,765
30 Day Avg. Volume620,038
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)7.55
Price to Sales (P/S)0.00
P/FCF Ratio-26.63
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.07
Enterprise Value/Ebitda-15.85
Forecast
1Y Price Target
$611.25Price Target Upside78.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-15.21
Revenue Forecast (FY)$3.47M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeveragePraxis’s very low debt versus a large equity base gives durable financial flexibility to fund costly late‑stage trials and initial commercial build without immediate solvency pressure. This limits balance‑sheet risk and reduces near‑term dependence on distressed financing if execution slows.
Substantial Cash Runway Into 2028A roughly $1.4B cash position that management expects to fund operations into 2028 underpins the company’s ability to complete multiple pivotal readouts, commercial preparations and regulatory interactions. This runway materially lowers near‑term refinancing risk and supports strategic optionality.
Strategic Collaboration To Broaden Ulixa DeliveryThe Remagine collaboration and equity stake create a complementary delivery pathway for ulixacaltamide, potentially expanding patient reach and adherence versus oral dosing. Structurally this strengthens the ulixacaltamide franchise, diversifies go‑to‑market options, and aligns incentives for co‑development.
Bears Say
High And Persistent Cash BurnConsistent, large negative operating and free cash flow means Praxis must carefully manage spend or raise capital before commercialization revenues emerge. Sustained burn increases dilution risk and constrains optionality if pivotal readouts or approvals are delayed, making execution timing critical.
Program Risk: Mixed POWER1 ResultsA primary endpoint miss and a program pause signal material technical and execution risk for vormatrigine. Reassessment can delay development timelines, reduce confidence in peak sales assumptions, and redirect R&D and commercial resources, weakening the pipeline's near‑term revenue prospects.
Regulatory Timing Uncertainty/extensionAn FDA extension for relutrigine illustrates structural regulatory timing risk: additional analyses or major amendments can push launch windows, increase pre‑launch spend, and compress commercialization timelines. Repeated delays would raise financing needs and slow revenue generation.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines, Inc.’s price range in the past 12 months?
Praxis Precision Medicines, Inc. lowest stock price was $37.19 and its highest was $366.52 in the past 12 months.
What is Praxis Precision Medicines, Inc.’s market cap?
Praxis Precision Medicines, Inc.’s market cap is $9.06B.
When is Praxis Precision Medicines, Inc.’s upcoming earnings report date?
Praxis Precision Medicines, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 28 days.
How were Praxis Precision Medicines, Inc.’s earnings last quarter?
Praxis Precision Medicines, Inc. released its earnings results on May 07, 2026. The company reported -$3.2 earnings per share for the quarter, beating the consensus estimate of -$3.589 by $0.389.
Is Praxis Precision Medicines, Inc. overvalued?
According to Wall Street analysts Praxis Precision Medicines, Inc.’s price is currently Undervalued.
Does Praxis Precision Medicines, Inc. pay dividends?
Praxis Precision Medicines, Inc. does not currently pay dividends.
What is Praxis Precision Medicines, Inc.’s EPS estimate?
Praxis Precision Medicines, Inc.’s EPS estimate is -3.66.
How many shares outstanding does Praxis Precision Medicines, Inc. have?
Praxis Precision Medicines, Inc. has 27,878,775 shares outstanding.
What happened to Praxis Precision Medicines, Inc.’s price movement after its last earnings report?
Praxis Precision Medicines, Inc. reported an EPS of -$3.2 in its last earnings report, beating expectations of -$3.589. Following the earnings report the stock price went down -1.417%.
Which hedge fund is a major shareholder of Praxis Precision Medicines, Inc.?
Currently, no hedge funds are holding shares in PRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$611.25 (78.47% Upside)
$611.25 (78.47% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 832.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
546.10%
12-Months-Change
Fundamentals
Return on Equity
-43.02%
Trailing 12-Months
Asset Growth
205.01%
Trailing 12-Months
Company Description
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
PRAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and clinical momentum: two NDAs accepted with PDUFA dates, rapid completion of a key EMBOLD study, an impressive 77% placebo‑adjusted seizure reduction in EMBRAVE Part A, multiple upcoming pivotal readouts, and a strengthened balance sheet ($1.4B, +51% vs. year‑end). Management is heavily investing in commercialization and late‑stage development (Q1 operating cash use +62% YoY), which raises short‑term cash burn and execution risk. Regulatory timing, heterogeneous populations in broad DEE, and U.S. pricing dynamics are notable uncertainties but are framed as manageable. On balance, the positive clinical data, regulatory progress, and substantial cash runway outweigh the cost and execution risks.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$611.25
▲(78.47% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
8.07% Insiders
25.19% Mutual Funds
0.04% Other Institutional Investors
51.80% Public Companies and Individual Investors